New Noninvasive Method of Intracranial Pressure Monitoring

Researchers from Klinikum Stuttgart and the University of Erlangen, Germany, report preliminary findings that show a noninvasive method of monitoring intracranial pressure (ICP) that could rival the gold standards of invasive intraventricular and intraparenchymal monitoring. To date no noninvasive method of ICP monitoring has proved adequate to replace invasive ones. The new noninvasive monitoring device uses advanced signal analysis algorithms to evaluate properties of acoustic signals that pass through the brain in order to determine ICP values. It is described in the article "Evaluation of a novel noninvasive ICP monitoring device in patients undergoing invasive ICP monitoring: preliminary results," by Oliver Ganslandt, M.D., and colleagues.

Normally human intracranial pressure (ICP) is 20 mm Hg or lower, but in the presence of brain disease or traumatic head injury, brain tissues may swell or cerebrospinal fluid - the liquid that surrounds and protects the brain - may increase in volume, causing ICP to increase. Increased ICP can cause serious symptoms and sometimes even death. Continuous monitoring of ICP in critical-care patients provides clinicians with the knowledge of whether and when action must be taken to decrease ICP.

To perform invasive ICP monitoring a hole must first be drilled in the patient's skull. A catheter is then inserted into brain tissue (parenchyma) or into a ventricle (a space within the brain that contains cerebrospinal fluid). Sensors in the catheter continuously measure ICP. Intraventricular monitoring is especially useful. An intraventricular catheter can be used both to monitor ICP and to reduce this pressure when it is too high by intermittently extracting excess cerebrospinal fluid.

Intraparenchymal and intraventricular monitoring are gold standards of ICP measurement. However, the procedures required to measure ICP with these methods are invasive. They require opening the skull and carry risks such as bleeding, infection, and damage to brain tissue.

The researchers propose use of an alternative noninvasive ICP monitoring system. They describe the HS-1000 device (HeadSense Medical, Ltd), which emits 6-second-long bursts of sound (66 dB) near one ear. The acoustic signals pass throughout the cranium and, along with physiological brain sounds, are detected by receiving sensors located in the opposite ear. Advanced signal analysis algorithms are used to evaluate properties of the acoustic signals to determine ICP values. Data corresponding to the 6-second epoch are recorded and displayed on the device monitor. The HS-1000 monitoring system can be used continuously, with repeated 6-second epochs, to maintain a constant evaluation of ICP.

The researchers tested the new noninvasive ICP monitoring tool in 14 patients receiving treatment for traumatic brain injury and/or subarachnoid hemorrhage in an intensive care unit. Invasive intraventricular or intraparenchymal monitoring of the patients' conditions was already in place. The researchers then compared ICP values obtained using the noninvasive HS-1000 device with ICP values obtained using an invasive (intraventricular or intraparenchymal) monitoring system.

A comparison of 2543 data points of continuous ICP monitoring showed a strong association between ICP values obtained using noninvasive and invasive methods. Differences in mean ICP values were +/- 3 mm Hg in 63% of data-paired readings and +/- 5 mm Hg in 85% of data-paired readings. The authors point out that similar differences have been found in studies comparing the two invasive methods (intraventricular and intraparenchymal).

The sensitivity and specificity of noninvasive ICP monitoring were determined to be 0.7541 and 0.8887, respectively. Overall, the findings show a good correlation between ICP values obtained using noninvasive and invasive methods of monitoring.

Although this study is preliminary and further investigation is warranted, the authors show that the HS-1000 ICP system provides useful information on normal and elevated ICP values. The authors suggest that use of the device could protect patients from infection and hemorrhage--potential risks of invasive ICP monitoring - and also could aid clinicians in deciding when invasive ICP monitoring may be appropriate.

When asked about the study, Dr. Ganslandt said, "The first results look promising, but further refinements in the algorithm will be necessary to allow a reliable clinical application."

Ganslandt O, Mourtzoukos S, Stadlbauer A, Sommer B, Rammensee R.
Evaluation of a novel noninvasive ICP monitoring device in patients undergoing invasive ICP monitoring: preliminary results.
Journal of Neurosurgery, published online, ahead of print, August 8, 2017; DOI: 10.3171/2016.11.JNS152268.

Most Popular Now

Researchers Invent AI Model to Design Ne…

Researchers at McMaster University and Stanford University have invented a new generative artificial intelligence (AI) model which can design billions of new antibiotic molecules that are inexpensive and easy to...

Alcidion and Novari Health Forge Strateg…

Alcidion Group Limited, a leading provider of FHIR-native patient flow solutions for healthcare, and Novari Health, a market leader in waitlist management and referral management technologies, have joined forces to...

Greater Manchester Reaches New Milestone…

Radiologists and radiographers at Northern Care Alliance NHS Foundation Trust have become the first in Greater Manchester to use the Sectra picture archiving and communication system (PACS) to report on...

Powerful New AI can Predict People'…

A powerful new tool in artificial intelligence is able to predict whether someone is willing to be vaccinated against COVID-19. The predictive system uses a small set of data from demographics...

ChatGPT can Produce Medical Record Notes…

The AI model ChatGPT can write administrative medical notes up to ten times faster than doctors without compromising quality. This is according to a new study conducted by researchers at...

Can Language Models Read the Genome? Thi…

The same class of artificial intelligence that made headlines coding software and passing the bar exam has learned to read a different kind of text - the genetic code. That code...

Advancing Drug Discovery with AI: Introd…

A transformative study published in Health Data Science, a Science Partner Journal, introduces a groundbreaking end-to-end deep learning framework, known as Knowledge-Empowered Drug Discovery (KEDD), aimed at revolutionizing the field...

Study Shows Human Medical Professionals …

When looking for medical information, people can use web search engines or large language models (LLMs) like ChatGPT-4 or Google Bard. However, these artificial intelligence (AI) tools have their limitations...

Wanted: Young Talents. DMEA Sparks Bring…

9 - 11 April 2024, Berlin, Germany. The digital health industry urgently needs skilled workers, which is why DMEA sparks focuses on careers, jobs and supporting young people. Against the backdrop of...

Shared Digital NHS Prescribing Record co…

Implementing a single shared digital prescribing record across the NHS in England could avoid nearly 1 million drug errors every year, stopping up to 16,000 fewer patients from being harmed...

Bayer and Google Cloud to Accelerate Dev…

Bayer and Google Cloud announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve patients. As part of the collaboration, Bayer will...

Ask Chat GPT about Your Radiation Oncolo…

Cancer patients about to undergo radiation oncology treatment have lots of questions. Could ChatGPT be the best way to get answers? A new Northwestern Medicine study tested a specially designed ChatGPT...